胃癌免疫治疗困境与未来方向

doi:10.11904/j.issn.1002-3070.2021.06.013

Abstract

Abstract: China is a country with a high incidence of gastric cancer.The number of new cases accounts for about 44% of the world.Moreover,the proportion of patients with advanced gastric cancer is large,the survival rate is low,and the economic burden is serious.Although chemotherapy regimens for advanced gastric cancer are constantly improving,the efficacy is still limited.Targeted drugs except trastuzumab have improved efficacy in HER2-positive advanced gastric cancer patients,and other targeted drugs have poor efficacy in advanced gastric cancer patients.In recent years,immunotherapy has set off a research boom in the field of gastric cancer,and it has also brought dawn to the treatment of gastric cancer.This article reviews the research progress of immunotherapy for advanced gastric cancer,and elaborates the current dilemmas and future exploration directions for immunotherapy for gastric cancer.

Key words: Gastric cancer, Immune checkpoint inhibitors, Molecular markers

CLC Number:

R735.2

YU Yuanyuan, MENG Qianhao, WANG Guangyu. Dilemma and future direction of gastric cancer immunotherapy[J]. Journal of Practical Oncology, 2021, 35(6): 552-556.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.06.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I6/552

References

1 周家琛,郑荣寿,庄贵华,等.2000-2015年中国肿瘤登记地区胃癌发病趋势及年龄变化[J].实用肿瘤学杂志,2020,34(1):1-5.
2 Muro K,Van Cutsem E,Narita Y,et al.Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer:a JSMO-ESMO initiative endorsed by CSCO,KSMO,MOS,SSO and TOS[J].Ann Oncol,2019,30(1):19-33.
3 Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2018(5th edition)[J].Gastric Cancer,2021,24(1):1-21.
4 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
5 Kang YK,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
6 Alsaab HO,Sau S,Alzhrani R,et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:mechanism,combinations,and clinical outcome[J].Front Pharmacol,2017,8:561.
7 Zhou KI,Peterson B,Serritella A,et al.Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy[J].Clin Cancer Res,2020,26(24):6453-6463.
8 Shitara K,Van Cutsem E,Bang YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.
9 Moehler M,Shitara K,Garrido M,et al.LBA6_PR Nivolumab(nivo)plus chemotherapy(chemo)versus chemo as first-line(1L)treatment for advanced gastric cancer/gastroesophageal junction cancer(GC/GEJC)/esophageal adenocarcinoma(EAC):first results of the CheckMate 649 study[J].Ann Oncol,2020,31(4):1191.
10 Boku N,Ryu MH,Kato K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer:interim results of a randomized,phase II trial(ATTRACTION-4)[J].Ann Oncol,2019,30(2):250-258.
11 Rha SY,Lee CK,Kim HS,et al.Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer:a multi-institutional phase Ib/II trial of first-line triplet regimen(pembrolizumab,trastuzumab,chemotherapy)for HER2-positive advanced gastric cancer(AGC)[J].J Clin Oncol,2020,38(18):3081.
12 Homann N,Lorenzen S,Schenk M,et al.Interim safety analysis of the DANTE trial:perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma-a randomized,open-label phase II trial of the German Gastric Group at the AIO and SAKK[J].J Clin Oncol,2020,38(18):4549.
13 Wang X,Wang Y,Tang Z,et al.578P Interim analysis of a phase II study of SHR-1210 combined with neoadjuvant chemoradiation in patients with locally advanced proximal stomach adenocarcinoma(Neo-PLANET)[J].Ann Oncol,2020,31(4):491.
14 Kelly RJ,Ajani JA,Kuzdzal J,et al.LBA9_PR adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer(EC/GEJC)following neoadjuvant chemoradiation therapy(CRT):first results of the CheckMate 577 study[J].Ann Oncol,2020,31(4)1193-1194.
15 Hara H,Shoji H,Takahari D,et al.Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma(NivoRam study)[J].J Clin Oncol,2019,37(4):129.
16 Fukuoka S,Hara H,Takahashi N,et al.Regorafenib plus Nivolumab in patients with advanced gastric or colorectal cancer:an Open-Label,Dose-Escalation,and Dose-Expansion phase Ib trial(REGONIVO,EPOC1603)[J].J Clin Oncol,2020,38(18):2053-2061.
17 Markham A,Keam SJ.Camrelizumab:First globle approval[J].Drugs,2019,79(12):1355-1361.
18 Alsina M,Moehler M,Hierro C,et al.Immunotherapy for gastric cancer:A focus on immune checkpoints[J].Target Oncol,2016,11(4):469-477.
19 Lawrence MS,Stojanov P,Polak P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.
20 Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J].Cell,2007,131(6):1190-1203.
21 Mishima S,Kawazoe A,Nakamura Y,et al.Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer[J].J Immunother Cancer,2019,7(1):24.
22 Kim ST,Cristescu R,Bass AJ,et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-1458.
23 Chen C,Zhang F,Zhou N,et al.Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer:a systematic review and meta-analysis[J].Oncoimmunology,2019,8(5):e1581547.
24 Tabernero J,Cutsem EV,Bang YJ,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:the phase III KEYNOTE-062 study[J].J Clin Oncol,2019,37(18):4007.
25 Wainberg ZA,Fuchs CS,Tabernero J,et al.Efficacy of pembrolizumab(pembro)monotherapy versus chemotherapy for PD-L1-positive(CPS ≥10)advanced G/GEJ cancer in the phase II KEYNOTE-059(cohort 1)and phase III KEYNOTE-061 and KEYNOTE-062 studies[J].J Clin Oncol,2020,38(18):427.
26 Cocco E,Scaltriti M,Drilon A.NTRK fusion-positive cancers and TRK inhibitor therapy[J].Nat Rev Clin Oncol,2018,15(12):731-747.
27 Ohtsu A,Shah MA,Van Cutsem E,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized,double-blind,placebo-controlled phase III study[J].J Clin Oncol,2011,29(30):3968-3976.

[1]	WU Liting, LI Dabing, DENG Xiaoxia, LI Baisong. Trend and prediction of gastric cancer burden in Beibei district of Chongqing city from 2013 to 2020 [J]. Journal of Practical Oncology, 2021, 35(6): 495-499.
[2]	CHEN Yixin, SUN Yihua, CHENG Yangyang, HE Kaitong, GUO Ting. Relationship between preoperative inflammation-related indicators and prognosis of patients with resectable gastric cancer [J]. Journal of Practical Oncology, 2021, 35(6): 517-522.
[3]	MU Huijuan, LI Haina, LV Yi, SUN Lihua, WANG Lijuan, LI Yanxia, YU Fei, PAN Guowei, LIU Li. Analysis for 10-year survival rate of gastric cancer and its influencing factors among residents in three cities of Liaoning province [J]. Journal of Practical Oncology, 2021, 35(4): 339-343.
[4]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[5]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[6]	DU Xin,QU Ze,ZHAO Xuanzhong,HOU Mingxing,WANG Feng. Correlation analysis and expression of miRNA-126,K-Ras and MMP-7 in gastric cancer [J]. Journal of Practical Oncology, 2021, 35(1): 23-27.
[7]	YIN Songxiang. Expression of Copine-8 in gastric cancer and its correlations with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(5): 430-435.
[8]	LI Jian, MA Qi, REN Jin, HU Shengjuan. Research progress on influencing factors of gastric cancer [J]. Journal of Practical Oncology, 2020, 34(5): 466-470.
[9]	SHI Linna,SUI Hong. Research status for evaluation methods of lymph node metastasis in the early gastric cancer [J]. Journal of Practical Oncology, 2020, 34(3): 286-290.
[10]	ZHOU Jiachen, ZHENG Rongshou, ZHUANG Guihua, ZHANG Siwei, ZENG Hongmei, CHEN Ru, WANG Shaoming, SUN Kexin, ZOU Xiaonong, WEI Wenqiang, HE Jie. Analysis on the trend of gastric cancer incidence and age change in cancer registration regions of China,2000 to 2015 [J]. Journal of Practical Oncology, 2020, 34(1): 1-5.
[11]	DAI Dan, JIA Shangchun, CHEN Yeji, HE Qin, ZHA Zhenqiu, LIU Zhirong. Incidence and death of gastric cancer in Anhui cancer registries,2015 [J]. Journal of Practical Oncology, 2020, 34(1): 6-10.
[12]	WANG Ming, SUN Tiye. Effects of PFKFB4 on invasion and migration of gastric cancer cells and its mechanism [J]. Journal of Practical Oncology, 2020, 34(1): 37-42.
[13]	GUO Yongdong, JIN Jing, LI Limin, HE Yutong. Progress in differentiation of non-protein-encoding RNA(DANCR)in common malignant tumors [J]. Journal of Practical Oncology, 2020, 34(1): 69-73.
[14]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[15]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.

Dilemma and future direction of gastric cancer immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments